Dublin, March 23, 2022 (GLOBE NEWSWIRE) -- The "In situ Hybridization - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
Global In Situ Hybridization (ISH) Market to Reach $1.1 Billion by 2026
Global market for In Situ Hybridization (ISH) estimated at US$846.6 Million in the year 2020, is projected to reach a revised size of US$1.1 Billion by 2026, growing at a CAGR of 5.8% over the analysis period.
The process involved in in situ hybridization is subjecting the cells to some kind of stress to denature the DNA, followed by incubation of the cells containing the denatured DNA in a solution containing labeled probes or sequences whose position on the chromosome is to be determined. In-situ hybridization helps in the precise localization of a specific nucleic acid segment in a histologic specimen.
Fluorescence In Situ Hybridization (FISH), one of the segments analyzed in the report, is projected to grow at a 5.6% CAGR to reach US$885.4 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Chromogenic In Situ Hybridization (cish) segment is readjusted to a revised 6.2% CAGR for the next 7-year period. This segment currently accounts for a 28.6% share of the global In Situ Hybridization (ISH) market.
The U.S. Market is Estimated at $361 Million in 2021, While China is Forecast to Reach $79.5 Million by 2026
The In Situ Hybridization (ISH) market in the U.S. is estimated at US$361 Million in the year 2021. The country currently accounts for a 41.52% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$79.5 Million in the year 2026 trailing a CAGR of 7.1% through the analysis period.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.6% CAGR while Rest of European market (as defined in the study) will reach US$85.7 Million by the end of the analysis period.
The market is poised to post healthy growth over the coming years, driven by various favorable factors steering market expansion. Increasing incidence of cancer and genetic abnormalities, need for rapid disease diagnosis through genetic techniques, as well as higher funding (both public and private) leading to introduction of highly advanced cytogenetic techniques and their broadening applications are some of the key factors poised to contribute to future growth.
Significant rise in target patient population across the world, and rising preference for CGH in clinical diagnosis, is expected to drive the market further, providing players with lucrative opportunities.
Growing awareness levels of genetic disorders and expanding pool of research laboratories would be beneficial for cytogenetics solutions. Rise in incidence of cancer and the subsequent demand for personalized medicine, is likely to enhance market prospects in a major way.
Key Topics Covered:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- Influencer Market Insights
- Impact of Covid-19 and a Looming Global Recession
- Clinical Diagnostics: Challenges and Opportunities Amid the Pandemic
- Research Efforts Underway for Using ISH in COVID-19 Detection
- ISH in Molecular Detection of COVID-19 Causing SARS-CoV-2
- Immuno RNA Fluorescence ISH for Visualization of COVID-19 Causing SARS-CoV-2
- French Research Team Develops CoronaFISH
- In Situ Hybridization: A Prelude
- Future Prospects Remain Favorable for Insitu Hybridization
- Chromogenic ISH: Gaining Over FISH
- FISH Technology Continues to Find Favor
- How is FISH Better than Conventional Techniques?
- Probe Types and Application
- Fluorescent In Situ Hybridization Emerges as Cytological Tool of Choice for Plethora of Scientific Applications
- Recent Market Activity
- World Brands
2. FOCUS ON SELECT PLAYERS (Total 38 Featured)
- Abbott Laboratories
- Abnova Corporation
- Advanced Cell Diagnostics, Inc.
- Agilent Technologies Inc
- Bio SB
- Biocare Medical, LLC
- BioGenex Laboratories
- Bio-Techne Corporation
- Genemed Biotechnologies, Inc.
- Leica Biosystems Nussloch GmbH
- Thermo Fisher Scientific
- Merck KGaA
- Oxford Gene Technologies
- PerkinElmer Inc.
3. MARKET TRENDS & DRIVERS
- Rising Incidence of Cancer Drives the Demand for In-situ Hybridization
- Diverse Applications of FISH Technology in Oncology
- Growing Demand for Targeted Therapies in Cancer Treatment Presents Lucrative Opportunities
- Growing Number of Genetic Disorders and Emphasis on Genetic Testing Bodes Well for the Growth of ISH Market
- List of Genetic Disorders by Event, Genetic Manifestation and Prevalence
- Top Ten Genetic Diseases Worldwide
- Rise in Prenatal Testing Drives Opportunities
- FISH in Detection of Prenatal Genetic Abnormalities
- In Situ Hybridization Advances Present Perfect Tools to Detect Genetic Anomalies
- Uptrend in Companion Diagnostics Market Augurs Well
- Companion Diagnostics Lead the Way to Personalized Medicine
- State-Sponsored Molecular Research Initiatives Bode Well for Market Growth
- Increasing Research on Application of ISH in infectious Disease Diagnostics to Drive Growth
- FISH in Detection of Microbiological Pathogens
- Growth in In-vitro Diagnostics (IVD) for Diagnosis of Chronic Diseases Promise Opportunities
- High Demand for IVD Devices Promises Opportunities for FISH Probes
- Rising R&D Investments in the Biotech Sector Drives Gains
- Emergence of Automated Diagnostic Kits
- Novel Approach of Highly-Multiplexed FISH for In-Situ Genomics
- Technology Advancements & Improvements Bolster Growth
- Rise in Healthcare Expenditure to Drive Growth
- Ageing Demographics to Drive Demand
4. GLOBAL MARKET PERSPECTIVE
III. REGIONAL MARKET ANALYSIS
IV. COMPETITION
For more information about this report visit https://www.researchandmarkets.com/r/k59m7v
